Form 4: Pfizer EVP Lidia Fonseca Granted 82,284 Stock Appreciation Rights

Pfizer Executive Vice President Lidia Fonseca was granted 82,284 Stock Appreciation Rights, exercisable at $26.58, vesting and settling on March 3, 2031.

Summary

• Lidia Fonseca, Executive Vice President of Pfizer Inc. (PFE), was granted 82,284 Stock Appreciation Rights (SARs).
• The transaction date for this grant was March 3, 2026.
• The SARs have an exercise price of $26.58.
• These SARs are subject to certain vesting requirements.
• The SARs will be settled in shares of Pfizer common stock on the fifth anniversary of the grant date, which is March 3, 2031.
• Following this transaction, Lidia Fonseca beneficially owns 82,284 derivative securities directly.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive development, as it represents a standard executive compensation practice that aligns management's long-term interests with shareholder value, without indicating any immediate operational or financial changes.

Positives

• The grant of 82,284 Stock Appreciation Rights to Executive Vice President Lidia Fonseca aligns her interests with those of shareholders, incentivizing long-term company performance.
• The SARs have an exercise price of $26.58, indicating a baseline for future stock appreciation.

Future Outlook

The Stock Appreciation Rights are subject to vesting requirements and are scheduled to be settled in shares of Pfizer common stock on March 3, 2031, indicating a long-term incentive structure for the executive.

Industry Context

StockSavvy.ai notes that the grant of Stock Appreciation Rights is a common form of executive compensation in the pharmaceutical industry, designed to incentivize long-term performance and align management's financial interests with shareholder value creation. This practice is consistent with compensation strategies observed at peer companies.

Comparison to Industry Standards

• The use of Stock Appreciation Rights (SARs) as a long-term incentive is a standard practice across major pharmaceutical companies, including competitors like Johnson & Johnson (JNJ) and Merck & Co. (MRK).
• The vesting period and settlement on the fifth anniversary of the grant date are typical for such equity awards, aiming to retain key executives and reward sustained performance over several years.

Stakeholder Impact

• Shareholders: The grant of SARs aims to align the Executive Vice President's financial incentives with long-term shareholder value creation, potentially leading to improved company performance.
• Employees: This transaction is specific to executive compensation and does not directly impact the broader employee base, though it reflects the company's executive incentive structure.

Next Steps

• The Stock Appreciation Rights will vest over time, leading to settlement in Pfizer common stock on March 3, 2031, provided vesting requirements are met.

Key Dates

Keywords

Pfizer, PFE, Lidia Fonseca, Stock Appreciation Rights, SARs, Executive Compensation, Insider Transaction, Form 4